1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Rupert Hargreaves
Rupert Hargreaves
Articles (1088)  | Author's Website |

Should You Follow Buffett Into Teva Pharmaceutical?

The company does not fit Warren Buffett's typical mold

Buying companies that have fallen out of favor with the rest of market has always been a skill of Warren Buffett (Trades, Portfolio) and his team at Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B).

With this being the case, it should have come as no surprise the company acquired a $358 million investment in Israel-based drug company Teva Pharmaceutical Industries (NYSE:TEVA) in the fourth quarter of last year. But yet, it is a surprise for many Buffett watchers because the company does not fit Berkshire's traditional value mandate.

Similar to Berkshire's $2 billion investment in Canadian subprime mortgage lender Home Capital (TSX:HCG), Teva is an interesting pick because it is a struggling company in a struggling industry whose survival is not entirely guaranteed.


A struggling business

Teva's problems have been sometime in the making. Over the past several years, the company has accumulated around $23 billion in debt, and last year it was forced to issue several profit warnings. Revenue has started to decline and the company is facing expiring patents and generic competition for its multiple sclerosis drug Copaxone, which has had sales of $3.8 billion annually but is expected to drop to $1.8 billion this year.

To help it try and survive, management has cut more than a quarter of its research and development programs as well as hundreds of jobs, which sparked protests across Israel. In total, management wants to slash $3 billion from the company's cost base by 2019.

It remains to be seen whether this will be enough to stave off bankruptcy. Some analysts have drawn comparisons between Teva and Valeant (VRX), the now infamous generic drug producer that, after spending billions of dollars trying to grow through acquisitions, is now in recovery mode after losing more than 80% of its equity value.

Teva's management is guiding for the company to produce between $2.6 billion and $2.8 billion in free cash flow for 2018, which is at least something, although when compared to the group's enormous debt pile, it is insignificant.

Still, it seems Berkshire believes the stock is undervalued at current levels. The company does have some things going for it. For example, the demand for low-price generic pharmaceuticals is only going to grow over the long term. If Teva can maintain its position as one of the largest businesses in this space, it should continue to see rising demand, which gives management room to instigate a turnaround. While $2.8 billion of free cash flow against $28 billion in debt is hardly going to transform the business overnight, it could be enough to convince creditors to give Teva breathing space and not pull the plug immediately.

Is there more to it?

There are some other factors to consider here. This investment may not be entirely value-based. Just like Home Capital, by having Buffett on the shareholder roster, Teva should be able to gain additional recognition from its shareholders and creditors, who are unlikely to want to pull the plug now there is such a well-financed and well-known investor supporting the company.

In addition, it could have something to do with Buffett's recently announced entry into the U.S. health care market. Berkshire's collaboration with Amazon (NASDAQ:AMZN) and JPMorgan (NYSE:JPM) is currently only an idea, but by being a substantial shareholder in one of the world's largest generic drug producers, Berkshire's health care business will have a potential benefit available to it that few other competitors also have.


So overall, it might not be a good idea to follow Buffett into Teva. Yes, the stock looks cheap right now and could be a profitable contrarian bet as it trades at a forward price-earnings multiple of only 6.5 and price-free cash flow ratio of 8.1. However, its high level of debt is unnerving, competition in the generic drugs space is only getting tougher and, as of yet, we do not know if management's actions on costs will help or hinder the business in the long term.

Further, there could be much more to Buffett's investment in the business than initially meets the eye and the average investor will never be able to access these intangible benefits.

Disclosure: The author owns no stocks mentioned.

About the author:

Rupert Hargreaves
Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors.

Rupert holds qualifications from the Chartered Institute for Securities & Investment and the CFA Society of the UK. He covers everything value investing for ValueWalk and other sites on a freelance basis.

Visit Rupert Hargreaves's Website

Rating: 5.0/5 (1 vote)



SeaBud premium member - 2 years ago

"When you owe the bank $1M, the bank owns you. When you owe the bank $1B, you own the bank."

TEVA, like VRX, make over $2B/year in cash. If you are the bank, do you want the debtor sold in a fire sale where you litigate preference and probably get less than full repayment and no interest on billions? Or are you willing to structure your debt to get a lower rate (longer time) fully repaid? The answer is simple when the debtor has such cash flow. The above is true when debt rates are fixed and not stacked near term causing lendor panic and assumes FCF continues.

Please leave your comment:

Performances of the stocks mentioned by Rupert Hargreaves

User Generated Screeners

pascal.van.garsseHigh FCF-M2
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
/* */